Cat. No.: HY-17595

Mebendazole

7 Cited Publications

Customer Review

Based on 7 publication(s) in Google Scholar

Mebendazole is a highly effective, broad-spectrum antihelmintic against nematode infestations. Mebendazole also exhibits inhibitory effect against glioblastoma multiforme (GBM), inhibits Hedgehog pathway and tubulin polymerization. Mebendazole is orally active and can cross CNS penetration.

For research use only. We do not sell to patients.

Purity: 99.78%
CAS No.: 31431-39-7
Formula: C₁₆H₁₃N₃O₃
Molecular Weight:295.29

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Mebendazole Chemical Structure

CAS No.: 31431-39-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (7)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

Tublin polymerization^[1]; Hedgehog^[2]; Parasite^[3]

All Parasite Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	EC₅₀	0.9 μM Compound: MBZ	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29288939]
A549/TR	EC₅₀	1.7 μM Compound: MBZ	Cytotoxicity against human A549/TR cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549/TR cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29288939]
Calu-1	EC₅₀	1.1 μM Compound: MBZ	Cytotoxicity against human Calu1 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human Calu1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29288939]
HepG2 2.2.15	IC₅₀	>1000 μM Compound: 5a	Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as surface antigen HBsAg secretion after 9 days by ELISA Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as surface antigen HBsAg secretion after 9 days by ELISA	[PMID: 25650312]
HepG2 2.2.15	CC₅₀	>1000 μM Compound: 5a	Cytotoxicity against human HepG2.2.15 cells assessed as cell death after 9 days by MTS assay Cytotoxicity against human HepG2.2.15 cells assessed as cell death after 9 days by MTS assay	[PMID: 25650312]
HepG2 2.2.15	IC₅₀	>1000 μM Compound: 5a	Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as HBeAg secretion after 9 days by ELISA Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as HBeAg secretion after 9 days by ELISA	[PMID: 25650312]
HL-60	EC₅₀	>30 μM Compound: 1, mebendazole	Cytotoxicity against human HL60 cells after 48 to 72 hrs by Alamar blue assay Cytotoxicity against human HL60 cells after 48 to 72 hrs by Alamar blue assay	[PMID: 22795629]
HUVEC	IC₅₀	8.8 μM Compound: Mebendazole	Inhibition of VEGFR2-mediated angiogenesis in human HUVEC cells after 24 hrs by inverted photomicroscopic analysis Inhibition of VEGFR2-mediated angiogenesis in human HUVEC cells after 24 hrs by inverted photomicroscopic analysis	[PMID: 22780961]
NCI-H157	EC₅₀	3.5 μM Compound: MBZ	Cytotoxicity against human NCI-H157 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H157 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29288939]
PC-3	EC₅₀	1.1 μM Compound: MBZ	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29288939]
PC-3M	EC₅₀	1.21 μM Compound: MBZ	Cytotoxicity against human PC3M cells assessed as reduction in cell viability after 48 hrs by cyquant reagent based fluorescence spectrometric assay Cytotoxicity against human PC3M cells assessed as reduction in cell viability after 48 hrs by cyquant reagent based fluorescence spectrometric assay	[PMID: 29288939]
SK-OV-3	EC₅₀	0.5 μM Compound: MBZ	Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29288939]

In Vitro

Mebendazole (1 nM-0.1 mM; 72 h) shows inhibition of GL261 mouse glioma cells with IC₅₀ value of 0.24 μM^[1].
Mebendazole (0.1 μM and 1 μM; 24 h) disrupts microtubule polymerization and microtubule structure in 060919 glioblastoma multiforme (GBM) cells^[1].
Mebendazole (10 nM-10 μM; 48 h) inhibits Hh signaling and reduces the expression of downstream Hh pathway effectors, by decreasing Gli1 transcript and protein expression in tumor tissues. Mebendazole inhibits Gli1 expression with an IC₅₀ value of 516 nM^[2].
Mebendazole (10 nM-10 μM; 48 h) prevents the formation of the primary cilium, and decreases the proliferation and survival of human medulloblastoma cells with constitutive Hh activation^[2].
A combination of mebendazole and Vismodegib (HY-10440) achieved additive inhibition of canonical Hh signaling^[2].
Mebendazole has effectively treated CNS echinococcosis in numerous clinical settings before, indicating significant CNS penetration property^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Immunofluorescence^[1]

Cell Line:

Glioblastoma multiforme (GBM) 060919 cells
Concentration:

1 μM
Incubation Time:

24 hours
Result:

Disrupted microtubule structure.

Immunofluorescence^[2]

Cell Line:

DAOY and hTERT-RPE1 cells
Concentration:

0, 0.1, 0.5, 0.75, and 1 μM
Incubation Time:

12 hours
Result:

Decreased GLI1 protein level and increased cleavage of caspase-3 protein level.

In Vivo

Mebendazole (50 mg/kg; p.o.; once daily for first 20 d and 5 d per week with 2 d off; 45 d) inhibits intracranial tumor growth in the syngeneic GL261 mouse model and 060919 human glioblastoma multiforme (GBM) xenograft mouse model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 mice (5-6 weeks old) implanted with GL261 glioma cells and 060919 human glioblastoma multiforme (GBM)^[1]
Dosage:

50 mg/kg; delivered with 50% (v/v) sesame oil and PBS^[2]
Administration:

Oral gavage; beginning 5 days after tumor implantation at a daily dose of 50 mg/kg for the first 20 days of treatment then changed to 50 mg/kg for 5 days, with 2 days off, each week.
Result:

Increased the mean survival to 49 days compared with the 30 days of control in syngeneic GL261 mouse model.
Increased the mean survival to 65 days compared with the 48 days of control in 060919 human glioblastoma multiforme (GBM) xenograft mouse model.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 31431-39-7
Appearance Solid
Molecular Weight 295.29
Formula C₁₆H₁₃N₃O₃
Color Off-white to light yellow
SMILES

O=C(OC)NC1=NC2=CC=C(C(C3=CC=CC=C3)=O)C=C2N1
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (7)

All Histological Imaging/StainingOthers

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

Lactylation-Driven YTHDC1 Alleviates MASLD by Suppressing PTPN22-Mediated Dephosphorylation of NLRP3. [Abstract]

2025 Nov 26:e10192. PMID: 41298230

Mebendazole purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 26:e10192. [Abstract]

Mebendazole (MBZ: 30,60 mg/kg). Representative images showing morphological changes in the liver. For histopathological studies, liver tissue sections were stained with H&E and Oil red O.
EMBO Mol Med

A novel model of glioblastoma recurrence to identify therapeutic vulnerabilities. [Abstract]

2025 Jun;17(6):1325-1354. PMID: 40295888

Mebendazole purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2025 Jun;17(6):1325-1354. [Abstract]

MBZ (Mebendazole) treatment for 48 hours resulted in a dose-dependent decrease in the number of cilia in recurrent GIC. Quantification of fluorescence images after cilia inhibition. Both cell lines were treated with either DMSO alone, 50 nM and 250 nM of MBZ for 48 hours before fixation.
Commun Biol

Parbendazole as a promising drug for inducing differentiation of acute myeloid leukemia cells with various subtypes. [Abstract]

2024 Jan 24;7(1):123. PMID: 38267545
Molecules

Rapid Discovery of CD38 Inhibitor via DNA-Encoded Natural Product Library Screening. [Abstract]

2026 Mar 5;31(5):864. PMID: 41828851
Microbiol Spectr

Repurposing flufenamic acid as a putative PmrB-directed adjuvant to restore colistin activity in Klebsiella pneumoniae. [Abstract]

2026 Mar 17:e0362025. PMID: 41842337
PLoS Negl Trop Dis

Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]

2019 Aug 20;13(8):e0007681. PMID: 31430351
J Gastroenterol Hepatol

The m6A reader IGF2BP1 contributes to the activation of hepatic stellate cells through facilitating TUBB4B mRNA stabilization. [Abstract]

2024 Dec;39(12):2916-2925. PMID: 39403946

Solvent & Solubility

In Vitro:

DMSO : 4.17 mg/mL (14.12 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3865 mL

16.9325 mL

33.8650 mL

5 mM

0.6773 mL

3.3865 mL

6.7730 mL

10 mM

0.3387 mL

1.6933 mL

3.3865 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 0.42 mg/mL (1.42 mM); Clear solution

This protocol yields a clear solution of ≥ 0.42 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (4.2 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 0.42 mg/mL (1.42 mM); Clear solution

This protocol yields a clear solution of ≥ 0.42 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (4.2 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 0.42 mg/mL (1.42 mM); Clear solution

This protocol yields a clear solution of ≥ 0.42 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (4.2 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 5 mg/mL (16.93 mM); Suspended solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 15% Cremophor EL 85% Saline

Solubility: 25 mg/mL (84.66 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Korean - KR (418 KB)
- Portuguese - PT (418 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Bai RY, et al. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro Oncol. 2011 Sep;13(9):974-82. [Content Brief]

[2]. Larsen AR, et al. Repurposing the antihelmintic mebendazole as a hedgehog inhibitor. Mol Cancer Ther. 2015 Jan;14(1):3-13. [Content Brief]

[3]. Erdinçler P, et al. The role of mebendazole in the surgical treatment of central nervous system hydatid disease. Br J Neurosurg. 1997 Apr;11(2):116-20. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.3865 mL	16.9325 mL	33.8650 mL	84.6625 mL
	5 mM	0.6773 mL	3.3865 mL	6.7730 mL	16.9325 mL
	10 mM	0.3387 mL	1.6933 mL	3.3865 mL	8.4663 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Mebendazole

NMPA-Approved Drug Library

Cytoskeleton Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Antiparasitic Compound library

Rare Diseases Drug Library

Pediatric Drug Library

Protein-protein Interaction Inhibitor Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Cell Death Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

High-Efficiency Gene Editing Compound Library

RNA Binding Bioactive Compound Library

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) Mebendazole

All Parasite Isoforms

Biological Activity

Chemical Information

Publications (7)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Mebendazole Related Classifications

HY-17595 Related Classifications